Technology Business News: Markets, Investment & Strategy
Technology Business News: Markets, Investment & Strategy. Follow coverage across AI and emerging technology, ranked by the Polyemergence importance method.
Italian rocket maker Avio reports that the upcoming Vega C launch has been pushed back to around Christmas. CEO Giulio Ranzo stated during an earnings call that the delay is caused by late satellite deliveries from customers. The mission will carry six spacecraft for Italy's IRIDE Earth observation network.
Coherus Oncology is cutting 30% of its workforce as it narrows its clinical focus primarily onto esophageal cancer. The decision follows early-stage trial data showing strong anti-tumor activity when combining its experimental antibody tagmokitug with its approved drug Loqtorzi, prompting the company to reduce costs and extend its cash runway.
AbCellera announced it will stop developing its experimental autoimmune drug ABCL575 after completing an early-stage trial. Although the drug met its primary safety goals, the company pointed to broader industry challenges in the OX40 drug class. Several major drug developers have recently scaled back or cancelled similar programs due to safety concerns or modest clinical benefits.
The U.S. Treasury's proposed rules to restrict outbound investments in China's biopharma sector have sparked intense concern among industry leaders and legal experts. While Washington aims to protect national and economic security, critics like RA Capital's Peter Kolchinsky warn that the vague regulations—particularly around joint ventures—will blind U.S. investors, cripple domestic innovation, and inadvertently hand a competitive advantage to European and Chinese rivals.
According to LangChain Blog: LangChain announced a $300M Series C funding round led by CapitalG, valuing the company at $3B. The company aims to help enterprises own their intelligence through AI agents and its LangSmith platform, which is already used by over 7,000 organizations.
As regulators and consumers push for less packaging waste, food and beverage companies are making targeted sustainable packaging changes. From Campbell's paper-based clips to PepsiCo's lightweight bottles, these brands are adjusting their materials to improve recyclability and comply with new rules while meeting consumer demand.
Cardiometabolic biotech Marea Therapeutics reports that its drug candidate MAR001 significantly reduced blood fat in a phase 2b study for patients with high triglycerides. The antibody lowered triglycerides by over 70% in patients with very high levels, while showing a side effect rate slightly below the placebo group. CEO Josh Lehrer notes the results are encouraging for patients facing pancreatitis and heart attack risks, with plans to advance further studies and explore potential applications in obesity.
At the ObesityWeek 2026 conference, biopharma companies are shifting attention beyond standard GLP-1 drugs to explore new pathways like amylin modulation. Industry experts emphasize that the next generation of weight loss therapies will focus heavily on improving treatment persistence and the quality of weight reduction, particularly preserving muscle mass.
Nvidia’s leadership crisis has sparked concern in Israel, where the company is a major employer and economic driver. While the tech community worries about future commitment to its local operations, venture capitalists believe Jensen Huang’s departure could create a window for competitors to challenge Nvidia’s dominance in the AI chip market.
According to a Reuters report, China has developed AI computing projects worth over $3 billion that rely on restricted Nvidia processors like the H100 and H200. These projects span across multiple provinces, showing that Chinese developers remain heavily dependent on American chip technology despite tightening US export controls, which could lead to potential supply disruptions and higher costs.
Smart ring maker Oura is acquiring telehealth startup Counsel Health, a platform previously promoted by drugmaker Eli Lilly for GLP-1 prescriptions. Experts warn this deal introduces potential conflicts of interest because patients sharing health data through Oura rings may now be treated by clinicians within the same newly-acquired ecosystem, complicating how pharmaceutical companies direct patient care.
Zura Bio has discontinued development of its experimental drug tibulizumab for hidradenitis suppurativa after a phase 2 trial missed its primary endpoint. The trial failed because the placebo group performed much better than expected, matching the drug's effectiveness. Following the news, Zura's stock plunged 72%, though the company stated it still has enough cash to fund operations through 2028.
Spruce Biosciences is spinning out its preclinical endocrinology program, including a monoclonal antibody for congenital adrenal hyperplasia, into a new entity called Adrenyx Biosciences. Backed by up to $50 million in private equity and led by Spruce's CFO, the separation allows Spruce to focus on neurological disorders while Adrenyx prioritizes endocrinology.
According to MIT Climate: At an MIT energy conference, Breakthrough Energy CTO Eric Toone reported that global decarbonization would cost roughly 7.5 trillion dollars, or 5 percent of world GDP. Utilizing artificial intelligence to analyze costs, the firm emphasizes that success relies heavily on eliminating the green premium because people are generally unwilling to pay extra for eco-friendly alternatives.
The global boom in artificial intelligence has made Taiwanese stocks a massive obsession for ordinary citizens. Driven by the critical role of Taiwan Semiconductor Manufacturing Company, people from all walks of life are closely tracking markets as chips become the ultimate strategic resource.
Stratasys and Nano Dimension have mutually agreed to cancel the 42.5 million USD acquisition of MarkForged. According to Stratasys, the decision comes after realizing that the regulatory process would take much longer and cost more than expected. Both companies now believe the required approvals won't happen anytime soon, prompting them to scrap the deal entirely.
Blackstone is backing Pfizer’s bet on a monthly obesity treatment. Meanwhile, the FDA commissioner nominee Heidi Overton is facing a tight Senate vote due to concerns over past vaccine policies, and Bristol Myers Squibb is shaking up its R&D leadership.
Swiss biotech Windward is planning a Nasdaq IPO to raise over $200 million, primarily to fund respiratory drugs licensed from China. The company aims to advance its phase 2 and phase 3 clinical trials for asthma and chronic obstructive pulmonary disease, backed by major pharmaceutical investors including Sanofi.
Bristol Myers Squibb is combining its research and development into a single unit as the pharmaceutical giant faces impending patent expirations for its top-selling drugs. Chief Research Officer Robert Plenge will step down, with Chief Medical Officer Cristian Massacesi taking over the unified team to accelerate drug development.
According to Meta Newsroom AI: Meta announces long-term purchase agreements with low-carbon producers to bring clean manufacturing to its data center supply chains, aiming to set an industry standard.
Biogen is preparing to release the results of twin Phase 3 studies for its lupus drug, litifilimab, in early December. This upcoming data serves as a crucial test for the research and development overhaul initiated by CEO Chris Viehbacher, carrying high stakes for the company's growth strategy.
Columnist Adam Feuerstein re-evaluates his previous prediction about biotech company Alnylam reaching a $100 billion valuation. He notes that Alnylam must successfully address its heart drug challenges to sustain its market growth and fulfill its earlier potential.
The European Space Agency has explained that negotiations with MaiaSpace are delayed because the company chose launch service contracts instead of technical development funding, unlike its competitors. While other firms secured most of their money for development, MaiaSpace opted entirely for launch support, making the paperwork more complicated.
Artificial intelligence is rapidly transforming the food and beverage industry, with about 90% of R&D leaders now regularly using the technology to cut costs and speed up product development. However, companies must carefully protect trade secrets and restructure their internal workflows to safely balance powerful AI tools with crucial human expertise.
PepGen's experimental drug for myotonic dystrophy type 1 achieved a record splicing correction of 46.5% in a mid-stage clinical trial, outperforming competitors and causing its stock price to nearly double. The positive safety profile and potential for higher doses offer new hope for treating this rare genetic disease.
According to AWS Machine Learning: Amazon SageMaker AI is launching usage-based metering for bidirectional streaming inference, solving a long-standing billing headache for real-time speech AI. Previously, live audio streams lasting minutes couldn't easily report periodic consumption through traditional request-response headers.…
Capricor Therapeutics saw its operating expenses surge 70% in the third quarter as it ramps up manufacturing for its upcoming Duchenne muscular dystrophy cell therapy. With an FDA decision looming, the company's San Diego facility is fully prepped for an initial launch, though past regulatory hurdles and a mixed advisory vote still cast some uncertainty over the approval.
Shengshu Technology's much-hyped AI-assisted feature film Sanxingdui: Future Past has bombed at the box office, bringing in just 1.68 million yuan in eleven days with abysmally low attendance. The commercial failure casts a shadow over the company's upcoming Hong Kong IPO and exposes the harsh reality that current AI video tools are great for short clips, but still a far cry from full-length cinematic storytelling.
Alibaba has applied to spin off its in-house chip unit, T-Head, for an independent listing in Hong Kong. As the company accelerates its external commercialization and grapples with heavy AI infrastructure costs, this move allows the chipmaker to directly tap capital markets.
If the US halts new data center projects due to power and policy constraints, the growth of computing power will face a massive roadblock. While current models will run fine, training the next generation of AI will slow down significantly, forcing the industry to prioritize energy efficiency and token limits.
According to AMD Blogs: AMD is now shipping its new EPYC 9006 SP7 server processors, designed specifically to handle heavy workloads like agentic AI and high-performance computing. These chips offer up to 256 cores and blazing-fast memory speeds to help companies run multiple AI agents smoothly and keep expensive GPUs fed with data.
According to D-Wave News: D-Wave released its third-quarter 2026 financial results, highlighting a 21% increase in revenue year-over-year and a massive surge in remaining performance obligations. The company also reported major business milestones, including a potential $100 million CHIPS Act grant from the U.S. government and new quantum deployments with global telecom and tech giants.
As edge AI chips and on-device models boom, people worry the cloud will lose out. In reality, on-device processing doesn't kill the cloud; it just changes how we pay. Just like household appliances increased total power consumption instead of shutting down power plants, edge devices handle daily tasks while cloud giants keep the core knowledge and fallback power.…
The global smartphone market is seeing rising average prices alongside dropping shipment numbers. Driven by data center expansion, memory costs are surging, squeezing phone chip makers while end-side AI demands continuous heavy investment without immediate sales returns.
AI computing is shifting from simply adding more chips to building tightly coupled systems called supernodes. Instead of traditional clusters wasting time on cross-node communication delays, supernodes tightly link hundreds or thousands of GPUs together into what acts as a single giant chip, dramatically boosting training efficiency. This massive shift transforms the AI hardware market from a game of raw chip specs to an intense race for system integration and interconnect protocols.
Despite market turbulence, AI startup Anthropic is pushing ahead with its IPO plans, aiming to start trading as early as next week. Investors will use its valuation to judge the health of the entire artificial intelligence market, as early target figures face downward pressure.
Alibaba's semiconductor subsidiary T-Head is reportedly planning a Hong Kong IPO in 2027 to raise between $2 billion and $3 billion, valuing the business up to $62 billion. This move marks Alibaba's latest effort to spin off its core tech assets, aiming to reduce internal cost pressure and establish independent market valuation amidst the global AI boom.
According to Anthropic News: AI startup Anthropic has officially kicked off the roadshow for its initial public offering, planning to trade on the Nasdaq under the symbol ANT. The company aims to price its shares between $70.00 and $78.00, marking a massive milestone for the generative AI industry as it heads toward the public market.
You can now link your organization to your Google Cloud account to cover Hugging Face usage. This allows companies to consolidate invoices and skip new vendor approvals.
According to AMD Blogs: AMD, Supermicro, and Spectro Cloud have teamed up to release the Instinct Coder 355, an on-premises AI coding platform for enterprises. It combines AMD hardware with local models like GLM-5.3 to handle routine coding tasks locally, helping companies reduce costs while protecting sensitive source code from leaving their internal servers.
According to NVIDIA Generative AI: NVIDIA is teaming up with South Korea's Ministry of Science and ICT to invest in local AI startups. This move will support companies working on everything from chip infrastructure to robotics, helping strengthen the global AI ecosystem.
As AI-driven cyberattacks increase, Indian companies are moving past remote monitoring and requesting on-site security engineers from startups. These specialists work directly inside client offices to protect systems and manage the security risks brought by autonomous AI agents.
The hype around world models is fading fast, with venture capitalists tightening their purse strings and making it much harder for early-stage startups to raise money. While the market is cooling down from its summer peak, top-tier talents from elite universities are still managing to secure massive funding. This shift shows that investors are no longer buying into vague concepts and now demand real technology and actual progress.
The Nasdaq suffered its worst drop since April 2025, wiping out over $2.5 trillion in market value as worries about an AI speculative bubble resurfaced. Driven by the midterm election results, investors are waking up to the physical constraints and rising regulatory risks facing data centers, signaling a much-needed reality check for the booming industry.
According to AWS Machine Learning: Amazon SageMaker Inference now supports NVIDIA Multi-Instance GPU (MIG), allowing users to divide a single physical GPU into multiple independent partitions. This solves the long-standing problem of wasted computing power when a model doesn't need an entire accelerator, enabling companies to deploy multiple models on one instance securely and cost-effectively.
According to Cerebras Blog: Cerebras CEO Andrew Feldman published a detailed response to a short seller report claiming that their massive wafer-scale AI chips wear out in two years. Feldman explained that they solved the extreme thermal expansion challenges years ago through steady temperature controls and flexible electrical connections.…
